Prior authorization — study‑quality documentation expected

Prior authorization: require study-like documentation — When prior authorization is invoked for prescription nerve‑stimulator devices (e.g., prescription ReliefBand, PrimaBella), the plan expects documentation that mirrors clinical‑study evidence: indication being treated, prior conservative therapies tried and failed, objective outcome measures, and timing relative to procedures or chemotherapy.

• Document medical necessity with clear clinical indication and supporting progress notes.
• Include prior conservative therapy attempts and responses (medication trials, dietary changes, nonprescription measures).
• Provide objective outcome measures and follow‑up results (e.g., nausea/vomiting frequency, rescue antiemetic use, QoR-40, VAS scores).

Prior authorization — not uniformly specified in excerpt

Prior authorization not specified in these excerpts — The source policy text does not consistently state a universal prior‑authorization requirement for all device uses; for some indications the CPB references covered HCPCS (E0765) if selection criteria are met but does not spell out a uniform PA workflow in the excerpts.

• Check member's benefit plan and the Clinical Policy Bulletin for plan‑specific PA rules.
• HCPCS E0765 is listed as covered only when selection criteria are met; confirmation of PA requirements should come from plan systems.

Denial triggers and exclusions

Denial triggers — Evidence limitations and non‑covered devices can prompt claim denial. OTC/disposable ReliefBand devices are excluded as durable medical equipment; uses and indications judged experimental/investigational in the CPB are not covered.

• OTC/disposable ReliefBand devices: not covered as DME.
• Indications listed as experimental/investigational in the CPB (see policy enumerated list): not covered.
• Insufficient clinical documentation or lack of prior conservative therapy where required may lead to denial.

No explicit authorization or billing requirements in excerpt

Not applicable / no explicit authorization or billing requirements described in this excerpt — Several provider‑action elements (billing submission instructions, modifier use, or explicit PA codes) are not present in the provided text and must be confirmed with the payer’s CPB or provider portal.

• If billing guidance (CPT/HCPCS/ICD-10 mapping, use of E0765) is needed, consult the payer’s provider resources.
• Absence of explicit instructions in this excerpt does not imply absence of requirements; verify in benefit plan and CPB.

Clinical Policy Bulletin — consult for coverage and administrative rules

Clinical Policy Bulletins (CPBs) govern coverage determinations and should be consulted for administrative rules, selection criteria, and procedural coding guidance.

• Use the CPB to confirm covered HCPCS (e.g., E0765) and to review indications considered medically necessary vs experimental.
• Refer to CPB review dates and history for the latest policy updates and to determine applicability to the member's date of service.

Required documentation to support medical necessity

Required documentation — Submit clinical records that justify medical necessity and support the chosen device: diagnosis, prior treatments, failed conservative measures, treatment goals, and device prescription details.

• Diagnosis and indication for device use (e.g., chemotherapy‑induced NV unresponsive to antiemetics).
• Detailed history of conservative therapy attempts and responses (medications, dietary measures, vitamin B6 for hyperemesis gravidarum).
• Prescribing clinician’s rationale and device model (prescription ReliefBand, PrimaBella).
• Relevant operative or chemotherapy timing linked to symptom onset.

Device placement and application records

Device placement documentation — For implanted or externally applied prescription devices, include procedural notes or device application details that document correct placement and duration of use.

• Date/time of device application, anatomical site (e.g., P6 acupoint, wrist), stimulation parameters if recorded (frequency, mA).
• Provider performing application and any immediate adverse events or tolerance notes.

Recommended outcomes and follow‑up documentation

Recommended documentation elements — In addition to required items, capture objective outcome measures and follow‑up data used in the evidence base (e.g., rescue antiemetic use, QoR‑40, VAS, clinical pregnancy rate metrics).

• Baseline and follow‑up symptom scores (nausea frequency, VAS), use of rescue medications, and functional recovery measures (QoR‑40).
• For reproductive indications, report clinical pregnancy rate, implantation rate, live birth rate, and number of oocytes retrieved if available.
• Any adverse events or device‑related complications.

Use systematic review / meta‑analysis evidence in documentation

Systematic review/meta‑analysis methods support documentation — Evidence summarized in systematic reviews (search strategy, RCT inclusion, pooled outcomes) underpins policy determinations; when available, reference high‑quality RCTs or meta‑analyses in the chart to bolster medical necessity.

• Cite relevant systematic reviews or RCTs when clinical rationale aligns with evidence (e.g., TEAS effects on IVF outcomes or PONV).
• Indicate how the individual patient’s presentation matches populations and outcomes in the cited studies.

Conservative therapy and step‑therapy expectations

Conservative therapy prerequisite and step therapy guidance — The policy lists conservative therapies that should be tried before coverage of prescription devices for some indications (e.g., antiemetics, dietary measures, ginger, vitamin B6); some indications require a prior standard therapy trial while other excerpts do not specify step‑therapy sequencing.

• For chemotherapy‑ or post‑operative NV and hyperemesis gravidarum, document prior adequate trials of antiemetics and other conservative measures.
• Where the CPB requires a trial of standard therapy before device use, include details (agents tried, doses, duration, and outcomes).
• If no step therapy is described in the member’s CPB, document clinical justification for device use.